Phase I, Open-label Trial to Evaluate the Safety and Immunogenicity of INO-5150 Alone or in Combination With INO-9012 in Men With Biochemically Relapsed (PSA) Prostate Cancer

Trial Profile

Phase I, Open-label Trial to Evaluate the Safety and Immunogenicity of INO-5150 Alone or in Combination With INO-9012 in Men With Biochemically Relapsed (PSA) Prostate Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs INO 5150 (Primary) ; INO 9012
  • Indications Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Inovio Pharmaceuticals
  • Most Recent Events

    • 08 Aug 2017 According to an Inovio Pharmaceuticals media release, the company expects to report data from this trial in the third quarter of 2017.
    • 10 Jun 2017 Biomarkers information updated
    • 06 Jun 2017 Results of preliminary analysis aseessing prostate surface antigen stabilization presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top